SCHEMBL7248148

SCHEMBL7248148

CCOC(=O)C(=Cc1ccccc1)c1ccc(F)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 6/20 0.64
KMT2A Q03164 6/20 0.64
MAPT P10636 6/20 0.64
LMNA P02545 3/20 0.64
NPSR1 Q6W5P4 2/20 0.64
CYP1A2 P05177 1/20 0.64
CYP2C9 P11712 1/20 0.64
CYP2C19 P33261 1/20 0.64
POLB P06746 2/20 0.54
HTT P42858 2/20 0.48
ALDH1A1 P00352 1/20 0.48
NR1H4 Q96RI1 1/20 0.47
AKR1C1 Q04828 2/20 0.47
PTGS2 P35354 1/20 0.47
AKR1C2 P52895 1/20 0.47
AKR1C3 P42330 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.46
CASP3 P42574 1/20 0.46
TRPV1 Q8NER1 1/20 0.46
SENP7 Q9BQF6 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7248152 0.94 MAPT (0.64) MEN1KMT2AMAPTLMNANPSR1
SCHEMBL24704034 0.90 MEN1 (0.70) MEN1KMT2AMAPTLMNANPSR1
SCHEMBL7527305 0.90 MEN1 (0.70) MEN1KMT2AMAPTLMNANPSR1
SCHEMBL648889 0.90 MEN1 (0.70) MEN1KMT2AMAPTLMNANPSR1
SCHEMBL6934835 0.86 MEN1 (0.57) MEN1KMT2AMAPTLMNANPSR1
SCHEMBL6934839 0.86 MEN1 (0.57) MEN1KMT2AMAPTLMNANPSR1
SCHEMBL9744529 0.81 KMT2A (0.55) MEN1KMT2AMAPTLMNANPSR1
SCHEMBL15084622 0.80 KMT2A (0.55) MEN1KMT2AMAPTLMNANPSR1
SCHEMBL14970302 0.79 KMT2A (0.55) MEN1KMT2AMAPTLMNAALDH1A1
SCHEMBL3218584 0.79 MAPT (1.00) MEN1KMT2AMAPTLMNANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6590102-B1 Hydrogenation of 2-cyano-3-(p-fluorophenyl)glutaric acid diethyl ester in the presence of catalysts to prepare isomer mixtures of ethyl 4-(p-fluorophenyl)-6-oxo-3-piperidine -carboxylate, used as intermediates of paroxetine ASAHI GLASS COMPANY LTD. (JP) 2003-07-08 US disclosed
US-6476228-B1 Process for producing piperidinecarbinols ASAHI GLASS COMPANY LTD. (JP) 2002-11-05 US disclosed
WO-2002076940-A2 PROCESS FOR PREPARING ARYLPIPERIDINE CARBINOL INTERMEDIATES AND DERIVATIVES PENTECH PHARMACEUTICALS, INC. (US) 2002-10-03 WO disclosed
US-20010053862-A1 Process for preparing arylpiperidine carbinol intermediates and derivatives PENTECH PHARMACEUTICALS, INC. 2001-12-20 US disclosed
EP-0802185-B1 Process for producing piperidinecarbinols ASAHI GLASS CO LTD (JP) 2001-10-17 EP disclosed
US-6197960-B1 REDUCTION OF CYANOGLUTARIC ACID; CYCLIZATION, ISOMERIZATION ASAHI GLASS COMPANY LTD. (JP) 2001-03-06 US disclosed
EP-0802185-A1 Process for producing piperidinecarbinols ASAHI GLASS COMPANY LTD. (JP) 1997-10-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010053862-A1 Process for preparing arylpiperidine carbinol intermediates and derivatives ADH1C, CBR1, MAL2 MEN1 1478/4885KMT2A 3605/4885MAPT 4854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.